Skip to main
AORT

Artivion (AORT) Stock Forecast & Price Target

Artivion (AORT) Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Artivion is a MedTech company operating in a competitive market with potential risks from bigger players such as Terumo and Medtronic. The company's reliance on its preservation services segment and its dependency on BioGlue revenue pose regulatory and competition risks. Additionally, the company's international operations and foreign revenue are subject to exchange rate risk and regulatory changes. Despite these risks, the company's strong fundamentals and ongoing product development and expansion efforts position it for continued growth and profitability.

Bears say

Artivion is currently experiencing some challenges with its revenue growth, with a slow start in the first quarter of 2026 and a lowered FY26 revenue and adjusted EBITDA guidance. However, there are still positive developments such as the acquisition of Endospan's NEXUS product and the growth potential of the On-X heart valve portfolio. In the long-term, the company's pipeline remains robust with ongoing clinical trials for exciting new products. The company also has a strong balance sheet with a significant amount of cash. Despite the short-term setbacks, Artivion has the potential to continue being a leading producer and distributor of cardiovascular medical devices and technology, making it an attractive investment opportunity in the long run.

Artivion (AORT) has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Artivion and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Artivion (AORT) Forecast

Analysts have given Artivion (AORT) a Strong Buy based on their latest research and market trends.

According to 6 analysts, Artivion (AORT) has a Strong Buy consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $45.83, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $45.83, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Artivion (AORT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.